The medical technology company Bibb Instruments increased revenue in the second quarter from low levels, while the operating loss widened and the company continued the commercialisation of EndoDrill.Revenue amounted to SEK 0.5 million (0.0).Operating profit, EBIT, was SEK -5.6 million (-3.9). The deterioration in results is mainly explained by the fact that most of the previous capitalisation of development expenses ceased after sales began, meaning that costs previously capitalised are now expensed directly.Net profit amounted to SEK -5.6 million (-3.8). Earnings per share were SEK -0.05 (-0.09).Cash and cash equivalents amounted to SEK 35.4 million (15.8) at the end of the quarter. During the quarter, a rights issue was carried out that provided the company with approximately SEK 41.9 million before issue costs.CEO Fredrik Lindblad states that sales in the US amounted to USD 51,460 during the quarter, corresponding to approximately SEK 0.5 million, which was the highest quarterly sales figure since the market launch began in 2025. Together with TaeWoong Medical USA, the company continues to establish EndoDrill GI at more hospitals.After the end of the quarter, Bibb Instruments signed its first European distribution agreement for EndoDrill GI with Palex Medical Spain. The first European order was subsequently received, worth EUR 15,600, corresponding to approximately SEK 0.2 million. The launch in Spain is to begin during the autumn.Bibb Instruments also plans to commence production of EndoDrill EBUS during the autumn and to submit an application for US marketing approval. The company assesses that its liquidity will finance operations throughout both 2026 and 2027. No financial forecast is provided."We can therefore focus fully on our prioritised activities. These include continued market development in the US, the launch in Spain, the establishment of more European distribution partnerships and the further development of the EndoDrill platform through EndoDrill EBUS," Lindblad.He continues."After many years of product development, regulatory work and clinical documentation, we are now in a new phase. The focus is increasingly on converting the investments made over many years into broader market establishment. The progress made during the first half of the year gives us a strong foundation for continued commercialisation and shows that, step by step, we are converting our strategy into tangible results," states the Bibb Instruments CEO.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeRevenue0.50.0-EBIT-5.6-3.9-Net profit-5.6-3.8-Earnings per share, SEK-0.05-0.09-Cash and cash equivalents35.415.8124.1%